Home
Exeltis

Exeltis Market Share Analysis for June 2026

1. Généralités

Health > Biotechnology and Pharmaceuticals

Domainexeltis.com

Year Founded2003

Employees1001 - 5000

Annual Revenue$500M - $1B

Exeltis

Exeltis (including company regionals)

exeltis.com

See more website traffic and engagement information

Exeltis Revenue up to June 2026 is 500M - 1B

revenue generated by Exeltis top domains

Exeltis top domains revenue over 3 years

Revenue for Exeltis top domains

exeltis.com500M - 1B

See more with Sales Intelligence

Total visits to Exeltis's top domains

Understand Exeltis market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

exeltis.com35.5K

See more with Sales Intelligence

Avg. visit duration in Exeltis's top domains

Analyze Exeltis engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

exeltis.com00:00:37

See more with Sales Intelligence

Avg. pageviews on Exeltis's top domains

See how Exeltis keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

exeltis.com1.79

See more with Sales Intelligence

Exeltis top competitors by domain

Top similar sites in June 2026, ranked by their affinity

exeltisusa.comCompany NameExeltis Usa, IncEmployees51 - 200HQUnited States, New Jersey, Florham ParkAnnual revenue--Total visits3.5KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Exeltis

These are the website technologies, by industry, used by Exeltis top domains

Payment & Currencies (10)

Cart Functionality

Widget (8)

Twemoji

eCommerce (6)

WooCommerce

Advertising (5)

DoubleClick

More Technologies

12

See all

News & Signals from Exeltis

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsExeltis launched update to the labeled strength of TWIRLA transdermal system on Jun 19th '26.FLORHAM PARK, N.J., June 19, 2026 (GLOBE NEWSWIRE) - Exeltis USA, Inc. (Exeltis), a global pharmaceutical company specializing in women's health, announced that the U.S. Food and Drug Administration (FDA) has approved an update to the labeled strength of TWIRLA(R)(levonorgestrel and ethinyl estradiol) transdermal system.

NewsTHX Pharma partnered with Exeltis UK Limited on Jun 9th '26.This achievement is a major regulatory milestone in the partnership between THX Pharma and Exeltis, building directly on the successful completion of the first key milestone announced on October 14, 2025, and confirms that both companies remain on track to deliver TX01 to patients with Niemann-Pick type C disease as planned.

NewsDilafor AB partnered with Exeltis UK Limited on Jan 21st '26.Karolinska Development (Nasdaq Stockholm: KDEV) today announced that its portfolio company Dilafor has signed a binding term sheet with Exeltis, a global women's health company, for an exclusive semi-global license (excluding China and Japan) to its lead candidate drug tafoxiparin.